Navigation Links
Orexigen Therapeutics to Present at the 25th Annual Piper Jaffray Healthcare Conference
Date:11/27/2013

SAN DIEGO, Nov. 27, 2013 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a company overview at the 25th Annual Piper Jaffray Healthcare Conference in New York. The presentation is scheduled for Tuesday, December 3rd  at 11:00 a.m. Eastern Time. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company's Web site at www.orexigen.com. A replay will be available for 14 days after the event.

About Orexigen® Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave, which the Company is evaluating in the Light Study, a cardiovascular outcomes trial being conducted under a Special Protocol Assessment (SPA) with the FDA. Based on successful results of the Light Study, the Company plans to resubmit the Contrave NDA to the FDA with potential approval by June 2014.The Company's other product candidate, Empatic, has completed Phase 2 clinical trials. Further information about the Company can be found at www.orexigen.com. Orexigen Contact:

Media Contact:  McDavid Stilwell

Denise PowellVP, Corporate Communications and Business Development

BrewLife(858) 875-8629

(510) 703-9491


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Orexigen Announces Successful Interim Analysis of Contrave Light Study
2. Orexigen Therapeutics to Host Contrave Light Study Interim Analysis Conference Call and Webcast
3. Orexigen Therapeutics Reports Business and Financial Results for the Third Quarter Ended September 30, 2013
4. Orexigen and Takeda Announce Multiple Contrave Data Presentations at the ObesityWeek Meeting in Atlanta
5. Orexigen Therapeutics Enters Into Agreement with Sanofi to Manufacture Contrave for Territories Outside North America
6. A Balanced Risk-Benefit Profile Will Propel Orexigen/Takedas Contrave to Become the Most Widely Used Emerging Therapy for the Treatment of Obese and Overweight Patients
7. Orexigen Therapeutics Announces Date of Third Quarter 2013 Financial Results Conference Call and Upcoming Presentation at Credit Suisse Healthcare Conference
8. Orexigen Therapeutics to Present at the Bank of America Merrill Lynch Global Healthcare Conference
9. Orexigen Therapeutics Announces European Filing Strategy and Reports Business and Financial Results for the Second Quarter Ended June 30, 2013
10. Orexigen Therapeutics to Host Second Quarter 2013 Financial Results Conference Call and Webcast
11. Orexigen Therapeutics Announces Upcoming Clinical Data Presentations at American Diabetes Association Annual Scientific Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... , March 5, 2015 BioLineRx ... clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and ... has commenced an underwritten public offering of American ... its Ordinary Shares. All of the ADSs in ... JMP Securities is acting as ...
(Date:3/5/2015)...  Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage ... therapeutics including high value and difficult to manufacture ... full year 2014 financial results will be released ... opens for trading.  At 9:00 am Eastern Time, ... discuss the financial results and provide a business ...
(Date:3/5/2015)... PharmaTech (Cayman) Inc. (NYSE: WX ), a ... the pharmaceutical, biotechnology, and medical device industries, with operations ... financial results for the fourth quarter and full year ... Net Revenues Increased 21.3% Year Over Year to $190.6 ... Year Over Year to $140.5 Million , Manufacturing ...
Breaking Medicine Technology:BioLineRx Announces Underwritten Public Offering of its American Depositary Shares 2BioLineRx Announces Underwritten Public Offering of its American Depositary Shares 3Pfenex To Report Fourth Quarter and Full Year 2014 Results and Provide Business Update 2WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 2WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 3WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 4WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 5WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 6WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 7WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 8WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 9WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 10WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 11WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 12WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 13WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 14WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 15WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 16WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 17WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 18WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 19WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 20WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 21WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 22
... ABBOTT PARK, Ill., March 11 The ... review the supplemental new drug application (sNDA) of a ... Depot (leuprolide acetate for depot ... prostate cancer.  Palliative treatment helps to relieve symptoms associated ...
... HARBIN, China , March 11 /PRNewswire-Asia-FirstCall/ -- ... a,developer, manufacturer and distributor of botanical products,bio-pharmaceuticals and traditional ... its Shengmai Granules price by 12%. Shengmai,Granule is an ... ...
Cached Medicine Technology:Abbott Seeks FDA Approval of a New Six-Month 45-mg Formulation of Lupron(R) Depot for the Palliative Treatment of Advanced Prostate Cancer 2Abbott Seeks FDA Approval of a New Six-Month 45-mg Formulation of Lupron(R) Depot for the Palliative Treatment of Advanced Prostate Cancer 3Abbott Seeks FDA Approval of a New Six-Month 45-mg Formulation of Lupron(R) Depot for the Palliative Treatment of Advanced Prostate Cancer 4Abbott Seeks FDA Approval of a New Six-Month 45-mg Formulation of Lupron(R) Depot for the Palliative Treatment of Advanced Prostate Cancer 5Abbott Seeks FDA Approval of a New Six-Month 45-mg Formulation of Lupron(R) Depot for the Palliative Treatment of Advanced Prostate Cancer 6Abbott Seeks FDA Approval of a New Six-Month 45-mg Formulation of Lupron(R) Depot for the Palliative Treatment of Advanced Prostate Cancer 7Renhuang Announces Price Increase on Shengmai Granules 2Renhuang Announces Price Increase on Shengmai Granules 3Renhuang Announces Price Increase on Shengmai Granules 4
(Date:3/5/2015)... Shania Twain will be touring throughout North ... She has hinted that this will be her final tour and ... last time. She has had a residency in Las Vegas ... millions of loyal fans around the world. After opening in ... on June 30th she will be at Madison Square Garden (MSG) ...
(Date:3/5/2015)... San Diego, CA (PRWEB) March 05, 2015 ... dangerous levels of formaldehyde in low-cost laminate ... Bamboo, the leading manufacturer of eco-friendly building materials ... to customer safety by testing all their flooring ... leading emissions detection laboratory Benchmark International ...
(Date:3/5/2015)... 2015 A Bakersfield, Calif. state court jury ... trial awarding the plaintiff Coleen M. Perry a total of ... a TVT-Abbrevo pelvic mesh sling device, manufactured by Ethicon, Inc., ... , a partner at Wagstaff & Cartmell in ... plaintiff, along with Rich Freese and Tim Goss of ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 AxoGen, ... focused on the peripheral nerve repair market, reported record ... December 31, 2014 compared to $2.98 million in the ... its growth strategies. , “Our strong fourth quarter ... peripheral nerve repair products which is driving increased surgeon ...
(Date:3/5/2015)... 2015 Risperdal lawsuits ( http://www.risperdallawsuit2014.com/ ... mass tort litigation currently underway in the Philadelphia ... begun hearing testimony in the proceeding’s second bellwether ... can cause gynecomastia, or male breast growth. According ... filed on behalf of a plaintiff who was ...
Breaking Medicine News(10 mins):Health News:Shania Twain Tickets: Ticket Down Announces Shania Twain's 2015 “Rock This Country” North American Tour 2Health News:Shania Twain Tickets: Ticket Down Announces Shania Twain's 2015 “Rock This Country” North American Tour 3Health News:With Homeowners Concerned About Formaldehyde, Cali Bamboo Puts Safety Above Bottom Line 2Health News:Client Wins $5.7 Million in TVT-Abbrevo Verdict against Johnson & Johnson in California State Court 2Health News:AxoGen, Inc. Reports 61% Revenue Growth for the 2014 Fourth Quarter 2Health News:AxoGen, Inc. Reports 61% Revenue Growth for the 2014 Fourth Quarter 3Health News:AxoGen, Inc. Reports 61% Revenue Growth for the 2014 Fourth Quarter 4Health News:Risperdal Lawsuits Move Forward in Pennsylvania, as Bernstein Liebhard LLP Comments on Start of Second Gynecomastia Trial 2Health News:Risperdal Lawsuits Move Forward in Pennsylvania, as Bernstein Liebhard LLP Comments on Start of Second Gynecomastia Trial 3
... Nashville ... Dental Association (NDA) at 6 p.m. on December 5 at the Loews Vanderbilt Plaza Hotel ... Nashville, Tenn. ... the 86th president of the National Dental Association (NDA) at 6 p.m. on December 5 ...
... ... N.Y. Times #1 best-seller KNOCKOUT , ... Cornwall, NY (PRWEB) December 2, 2009 -- In her new book KNOCKOUT, Interviews ... Place, Suzanne Somers interviews doctors who are successfully using the most innovative cancer treatments--treatments that ...
... ... released his first full-length book, Short White Coat: Lessons from Patients on Becoming a Doctor, ... , ... December 2, 2009 -- Most people will, at some point or another, either find themselves ...
... , CAMPBELL, Calif., Dec. ... Dr. Rafael Pelayo, Associate Professor at the Stanford Sleep Disorders Clinic ... Sound Machine as part of a healthy sleep plan for people ... drugs. , "Background noise is a problem for people when they ...
... CHICAGO, Dec. 2 A randomized, controlled study comparing standard ... decompression for painful herniated disc revealed that while both treatments ... patients pain free up to two years later. Results of ... at the annual meeting of the Radiological Society of North ...
... , SEATTLE, Dec. 2 ... that Ruth Pettengell, M.D. of St. George,s Hospital, University of ... will present new data on the pixantrone phase III trial ... Meeting of the American Society of Hematology on Saturday, December ...
Cached Medicine News:Health News:Meharry Medical College Officer Will Head the National Dental Association 2Health News:Meharry Medical College Officer Will Head the National Dental Association 3Health News:Innovative Biofeedback Technology Wins By A "Knockout." 2Health News:Innovative Biofeedback Technology Wins By A "Knockout." 3Health News:Innovative Biofeedback Technology Wins By A "Knockout." 4Health News:Beneath the Short White Coat: A Medical Student Reveals All 2Health News:Sleep Specialist Dr. Rafael Pelayo Recommends ASTI's Ecotones Duet Sleep Sound Machine 2Health News:Sleep Specialist Dr. Rafael Pelayo Recommends ASTI's Ecotones Duet Sleep Sound Machine 3Health News:Outpatient Disc Treatment Gives Long-Term Back Pain Relief 2Health News:Outpatient Disc Treatment Gives Long-Term Back Pain Relief 3Health News:New Pixantrone Phase III Data to be Presented at the 51st Annual Meeting of the American Society of Hematology 2Health News:New Pixantrone Phase III Data to be Presented at the 51st Annual Meeting of the American Society of Hematology 3Health News:New Pixantrone Phase III Data to be Presented at the 51st Annual Meeting of the American Society of Hematology 4
Alexander periosteal elevators....
Lambotte periosteal elevators....
Cottle periosteal & skin elevator, 7 1/2", slightly curved blade, 9 mm wide....
Dolwick-Reich Condyle periosteal elevator, 17.5 cm, 7"....
Medicine Products: